Medicine & Life Sciences
Etanercept
60%
Antirheumatic Agents
57%
Risk Assessment
40%
Rheumatoid Arthritis
40%
Methotrexate
31%
Safety
28%
Signs and Symptoms
21%
Juvenile Arthritis
19%
Tumor Necrosis Factor-alpha
17%
Infections
11%
Leflunomide
11%
Injection Site Reaction
11%
Interleukin 1 Receptor Antagonist Protein
10%
Diffuse Scleroderma
10%
Hydroxychloroquine
10%
Sulfasalazine
10%
Latent Tuberculosis
10%
Granulomatosis with Polyangiitis
10%
Psoriatic Arthritis
9%
Interleukin-1 Receptors
9%
Infliximab
9%
Ankylosing Spondylitis
9%
Uveitis
9%
Preliminary Data
8%
Immunologic Factors
8%
Rheumatic Diseases
8%
Gold
8%
United States Food and Drug Administration
8%
Cyclosporine
7%
Therapeutics
6%
Disease Progression
6%
Anti-Inflammatory Agents
5%
Monoclonal Antibodies
5%
Placebos
5%
Pharmaceutical Preparations
3%
Population
3%
Neoplasms
2%
Chemical Compounds
Methotrexate
60%
Safety
41%
Interleukin 1 Receptor Blocking Agent
22%
Hydroxychloroquine
21%
Leflunomide
21%
Sulfasalazine
19%
Haematological
17%
Nonsteroid Antiinflammatory Agent
13%